Anup Marda
Förmögenhet: 189 000 $ per 2026-05-31
Förmögenhet: 189 000 $ per 2026-05-31
Anup Marda is currently Chief Financial & Accounting Officer at Cabaletta Bio, Inc. since 2019.
Formerly, Mr. Marda was Executive Director at US Pharmaceuticals, Inc. from 2012 to 2014 and VP, Head-Global Financial Planning & Analysis at Bristol Myers Squibb Co. from 2018 to 2019.
Education includes an undergraduate degree from Indian Institute of Technology Bombay and an MBA from Krannert School of Management.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
CABALETTA BIO, INC. 0,05 % | 2026-03-02 | 50 000 ( 0,05 % ) | 189 000 $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| CABALETTA BIO, INC. | Finansdirektör/CFO | 2019-01-01 |
| Företag | Position | Slut |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Företagsledare/Principal | 2019-01-01 |
US Pharmaceuticals, Inc.
US Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes medicines | Direktör/Styrelseledamot | 2014-01-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
US Pharmaceuticals, Inc.
US Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes medicines | Health Technology |
Indian Institute of Technology Bombay
Indian Institute of Technology Bombay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Krannert School of Management
Krannert School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which discovers and develops engineered cell therapies for B cell-mediated autoimmune diseases | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån